Effects of cannabidiol-enriched cannabis extraction product on cognitive functions and inflammatory markers in Parkinson disease.

Phase 1

Completed

• Conditions: Parkinson disease; Cannabidiol enriched cannabis extraction product, Inflammatory marker, Parkinson disease, Cannabidiol, Cognitive function

• Registration Number: TCTR20230204001
• Lead Sponsor: Thai Traditional Medical Knowledge Fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-02-04
• Study Completion: 2023-10-20
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

The inclusion criteria were age more than 40 years, diagnosis of PD using the UK PD Society Brain Bank diagnostic criteria, Hoehn and Yahr Stages 1 to 3, stable dosage of PD medications for at least 3 months, and willingness of patients and caregivers to participate in the study.

Exclusion Criteria

Patients were excluded if they had dementia, schizophrenia, or other psychotic disorders; kidney or liver disease; serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels >3 times the upper limit of the normal range; or a history of high-risk behavior related to substance abuse, including nicotine, cannabis, and alcohol.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Delay Recall 12 weeks Thai Montreal Cognitive Assessment delayed recall

Secondary Outcome Measures

Name	Time	Method
Inflammatory markers 12 weeks ( white blood cell counts, erythrocyte sedimentation rate, C- reactive protein, ferritin level),Disease severity 12 weeks UPDRS III,Anxiety and depression 12 weeks HADS,Cognitive function 12 weeks MOCA ,LAB 12 weeks Renal and liver functions,side effect 12 weeks side effect,CBD level 12 weeks Serum CBD